My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1847

    1.

    Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.

    Diabetes. 2005 Nov;54(11):3148-53.PMID: 16249438 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.

    Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4649-55.PMID: 15356076 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.

    Vaag A, Skött P, Damsbo P, Gall MA, Richter EA, Beck-Nielsen H.

    J Clin Invest. 1991 Oct;88(4):1282-90.PMID: 1918378 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.

    Diabetes. 2003 Aug;52(8):1943-50.PMID: 12882909 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.

    Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC.

    Eur J Endocrinol. 2003 Dec;149(6):511-9.PMID: 14640991 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

    Diabetes Care. 2001 Apr;24(4):710-9.PMID: 11315836 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox.

    Dullaart RP, Riemens SC, Meinardi JR, Wolffenbuttel BH, Sluiter WJ.

    Scand J Clin Lab Invest. 2005;65(6):523-31.PMID: 16179286 [PubMed - indexed for MEDLINE]Related articles

    10.

    Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.

    Davoren PM, Kelly W, Gries FA, Hubinger A, Whately-Smith C, Alberti KG.

    Metabolism. 1998 Mar;47(3):250-6.PMID: 9500558 [PubMed - indexed for MEDLINE]Related articles

    11.

    Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.

    Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, Howard BV.

    Diabetologia. 1998 Oct;41(10):1127-32.PMID: 9794097 [PubMed - indexed for MEDLINE]Related articles

    12.

    Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.

    Blachère JC, Pérusse F, Bukowiecki LJ.

    Metabolism. 2001 Aug;50(8):945-51.PMID: 11474483 [PubMed - indexed for MEDLINE]Related articles

    13.

    Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.

    Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H.

    J Clin Endocrinol Metab. 1994 Mar;78(3):717-21.PMID: 8126147 [PubMed - indexed for MEDLINE]Related articles

    14.

    Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration.

    Bajaj M, Medina-Navarro R, Suraamornkul S, Meyer C, DeFronzo RA, Mandarino LJ.

    Diabetes. 2007 Mar;56(3):743-52.PMID: 17327445 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.

    Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA.

    Int J Obes Relat Metab Disord. 2004 Jun;28(6):783-9.PMID: 15024400 [PubMed - indexed for MEDLINE]Related articles

    16.

    Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

    Diabetes. 2003 Jun;52(6):1364-70.PMID: 12765945 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.

    Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H.

    Diabetes. 1996 May;45(5):659-66. Erratum in: Diabetes 1996 Sep;45(9):1285. PMID: 8621019 [PubMed - indexed for MEDLINE]Related articles

    18.

    Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.

    Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R.

    J Clin Endocrinol Metab. 1996 Nov;81(11):3998-4001.PMID: 8923850 [PubMed - indexed for MEDLINE]Related articles

    19.

    Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.

    Carey PE, Gerrard J, Cline GW, Dalla Man C, English PT, Firbank MJ, Cobelli C, Taylor R.

    Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E941-7. Epub 2005 Jul 5.PMID: 15998660 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.

    Piatti PM, Monti LD, Davis SN, Conti M, Brown MD, Pozza G, Alberti KG.

    Diabetologia. 1996 Jan;39(1):103-12.PMID: 8720610 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity